Cookies?
Library Header Image
LSE Research Online LSE Library Services

Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes

Bauer, Annette ORCID: 0000-0001-5156-1631, Wittenberg, Raphael ORCID: 0000-0003-3096-2721, Ly, Amanda, Gustavsson, Anders, Bexelius, Christin, Tochel, Claire, Knapp, Martin ORCID: 0000-0003-1427-0215, Nelson, Mia and Sudlow, Catherine (2020) Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes. International Journal of Technology Assessment in Health Care, 36 (4). 297 - 303. ISSN 0266-4623

[img] Text (Valuing Alzheimer's disease drugs) - Accepted Version
Download (178kB)
[img] Text (Supplement file rev) - Accepted Version
Download (330kB)
[img] Text (Table 3) - Accepted Version
Download (36kB)
[img] Text (Table 2) - Accepted Version
Download (69kB)
[img] Text (Table 1) - Accepted Version
Download (29kB)

Identification Number: 10.1017/S0266462320000574

Abstract

ObjectivesDue to the nature of Alzheimer's disease (AD), health technology assessment (HTA) agencies might face considerable challenges in choosing appropriate outcomes and outcome measures for drugs that treat the condition. This study sought to understand which outcomes informed previous HTAs, to explore possible reasons for prioritizations, and derive potential implications for future assessments of AD drugs.MethodWe conducted a literature review of studies that analyzed decisions made in HTAs (across disease areas) in three European countries: England, Germany, and The Netherlands. We then conducted case studies of technology assessments conducted for AD drugs in these countries.ResultsOverall, outcomes measured using clinical scales dominated decisions or recommendations about whether to fund AD drugs, or price negotiations. HTA processes did not always allow the inclusion of outcomes relevant to people with AD, their carers, and families. Processes did not include early discussion and agreement on what would constitute appropriate outcome measures and cut-off points for effects.ConclusionsWe conclude that in order to ensure that future AD drugs are valued appropriately and timely, early agreement with various stakeholders about outcomes, outcome measures, and cut-offs is important.

Item Type: Article
Official URL: https://www.cambridge.org/core/journals/internatio...
Additional Information: © 2020 The Authors
Divisions: Personal Social Services Research Unit
Subjects: R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Date Deposited: 24 Sep 2020 14:09
Last Modified: 20 Aug 2021 02:41
URI: http://eprints.lse.ac.uk/id/eprint/106620

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics